| 4.9 0.16 (3.38%) | 09-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9 | 1-year : | 11.3 |
| Resists | First : | 7.7 | Second : | 9.68 |
| Pivot price | 5.07  |
|||
| Supports | First : | 4.51 | Second : | 3.76 |
| MAs | MA(5) : | 4.81 |
MA(20) : | 5.38 |
| MA(100) : | 7.94 |
MA(250) : | 9.96 |
|
| MACD | MACD : | -0.8 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 13.7 |
D(3) : | 9.8 |
| RSI | RSI(14): 36.3 |
|||
| 52-week | High : | 25.89 | Low : | 4.51 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NIKI ] has closed above bottom band by 40.5%. Bollinger Bands are 27.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.9 - 4.92 | 4.92 - 4.95 |
| Low: | 4.73 - 4.75 | 4.75 - 4.77 |
| Close: | 4.86 - 4.89 | 4.89 - 4.93 |
Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.
Fri, 25 Sep 2026
Investors can watch Niki BioSolutions present online at noon Eastern time on Sept. 29 - Stock Titan
Thu, 24 Sep 2026
Funds from operations of Niki BioSolutions, Inc. – NASDAQ:NIKI - tradingview.com
Mon, 14 Sep 2026
Alzheimer’s blood-test merger reshapes who owns Niki BioSolutions (NASDAQ: NIKI) - Stock Titan
Mon, 14 Sep 2026
Niki BioSolutions engages Fios Genomics for Alzheimer’s analysis - Investing.com
Fri, 14 Aug 2026
Niki BioSolutions (NIKI) Cash Flow Statement - Moomoo
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 47.5 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 4 (K) |
| Shares Short P.Month | 6 (K) |
| EPS | -2.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 26.75 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -10.1 % |
| Return on Equity (ttm) | -17.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -1.69 |
| PEG Ratio | 0 |
| Price to Book value | 0.18 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|